Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany

Show simple item record

dc.identifier.uri Neubauer, Sarah Cifaldi, Mary Mittendorf, Thomas Ganguli, Arijit Wolff, Malte Zeidler, Jan 2016-12-22T07:48:55Z 2016-12-22T07:48:55Z 2014
dc.identifier.citation Neubauer, S.; Cifaldi, M.; Mittendorf, T.; Ganguli, A.; Wolff, M.; et al.: Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. In: Health Economics Review 4 (2014), Nr. 1, 32. DOI:
dc.description.abstract Objective: To obtain detailed real-world data on persistence and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in rheumatoid arthritis (RA) patients treated in Germany. Methods: In this retrospective observational study claims data of a major German health insurance fund between 2005 and 2008 were analysed. Patients receiving at least one prescription of adalimumab, etanercept or infliximab were identified and categorised as "TNF inhibitor naive" or "TNF inhibitor continuing". For the calculation of TNF inhibitor persistence a survival analysis with the Kaplan-Meier estimator was used. A Cox regression was used to analyse, if any relevant factors were influencing persistence. Dosage increase rates were analysed for adalimumab, etanercept and infliximab. Sensitivity analyses based on variations in gap length were conducted. Results: A total of 2,201 RA patients were identified. 1,468 of these patients were TNF inhibitor naive patients and 733 were defined as TNF inhibitor continuing patients. There were no significant differences in the treatment persistence rates between adalimumab, etanercept and infliximab for TNF inhibitor naive and continuing patients. The persistence rate after three years was 22.47% for adalimumab, 24.27% for etanercept and 21.49% for infliximab naive patients. For continuing patients, the persistence rate after three years was 32.88% for adalimumab, 30.95% for etanercept, and 33.90% for infliximab, respectively. Gender, medication and Charlson Comorbidities Index did not influence the persistence significantly. Dosage increase occurred in 7.3% adalimumab, 1.4% etanercept, and 17.2% infliximab naive patients and 5.8%, 1.1% and 11.9% respectively in the continuing patients. Conclusions: In this study, there were no significant differences in persistence among adalimumab, etanercept and infliximab treated patients. Consistent with previous research, there was a higher dose escalation for infliximab than for the two subcutaneous treatments, adalimumab or etanercept. eng
dc.language.iso eng
dc.publisher Berlin : Springer Verlag
dc.relation.ispartofseries Health Economics Review 4 (2014)
dc.rights CC BY 4.0 Unported
dc.subject Claims data eng
dc.subject Dosing patterns eng
dc.subject Germany eng
dc.subject Persistence eng
dc.subject Rheumatoid arthritis eng
dc.subject Tumor necrosis factor inhibitor eng
dc.subject adalimumab eng
dc.subject etanercept eng
dc.subject infliximab eng
dc.subject human eng
dc.subject ICD-10 eng
dc.subject Kaplan Meier method eng
dc.subject prescription eng
dc.subject rheumatoid arthritis eng
dc.subject sensitivity analysis eng
dc.subject survival eng
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany eng
dc.type article
dc.type Text
dc.relation.issn 21911991
dc.bibliographicCitation.issue 1
dc.bibliographicCitation.volume 4
dc.bibliographicCitation.lastPage 32
dc.description.version publishedVersion
tib.accessRights frei zug�nglich

Files in this item

This item appears in the following Collection(s):

Show simple item record


Search the repository


My Account

Usage Statistics